Table 3.
Univariate and multivariate analyses using Cox proportional hazards models using factors influencing OS and RFS
| Clinicaopathological features | OS univariate analysis | Multivariate analysis | RFS univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| PNI | ||||||||
| ≤48.5 vs. >48.5 | 0.606 (0.412-0.890) | 0.011 | 0.574 (0.387-0.851) | 0.006 | 0.725 (0.528-0.995) | 0.046 | 0.650 (0.472-0.897) | 0.009 |
| Age (years) | ||||||||
| ≤60 vs.>60 | 1.468 (1.002-2.150) | 0.049 | 1.074 (0.780-1.477) | 0.662 | ||||
| Sex | ||||||||
| Female vs. Male | 1.323 (0.886-1.977) | 0.172 | 1.235 (0.891-1.711) | 0.205 | ||||
| Primary tumor site | ||||||||
| Colon vs. Rectum | 1.310 (0.892-1.922) | 0.168 | 1.100 (0.800-1.514) | 0.557 | ||||
| Primary tumor size (cm) a | ||||||||
| ≤4 vs. >4 | 0.796 (0.509-1.245) | 0.318 | 0.798 (0.557-1.142) | 0.216 | ||||
| T stage | ||||||||
| 1-3 vs. 4 | 1.222 (0.824-1.812) | 0.320 | 1.093 (0.789-1.514) | 0.593 | ||||
| N stage | ||||||||
| 0 vs. 1-2 | 1.505 (1.014-2.234) | 0.043 | 1.653 (1.110-2.461) | 0.013 | 1.655 (1.197-2.289) | 0.002 | 1.856 (1.336-2.578) | <0.001 |
| Histological grade | ||||||||
| Well/moderate vs. Poor | 1.295 (0.788-2.130) | 0.308 | 1.042 (0.674-1.611) | 0.853 | ||||
| Size of liver metastases (cm) | ||||||||
| ≤2.5 vs. >2.5 | 1.428 (0.975-2.092) | 0.067 | 1.537 (1.125-2.101) | 0.007 | ||||
| Number of liver metastases | ||||||||
| Single vs. Multiple | 1.834 (1.238-2.718) | 0.002 | 1.940 (1.281-2.938) | 0.002 | 1.823 (1.325-2.508) | <0.001 | 1.750 (1.249-2.452) | 0.001 |
| Extrahepatic metastasis | ||||||||
| Yes vs. No | 0.575 (0.321-1.030) | 0.063 | 0.618 (0.369-1.038) | 0.069 | ||||
| Liver metastasis timing | ||||||||
| Metachronous vs. Synchronous | 0.733 (0.500-1.073) | 0.110 | 0.762 (0.558-1.041) | 0.088 | ||||
| Chemotherapy before hepatic resection | ||||||||
| Yes vs. No | 0.796 (0.534-1.186) | 0.262 | 0.610 (0.441-0.844) | 0.003 | ||||
| Chemotherapy after hepatic resection | ||||||||
| Yes vs. No | 1.709 (1.118-2.614) | 0.013 | 1.705 (1.107-2.624) | 0.015 | 1.162 (0.809-1.668) | 0.417 | ||
| RFA therapy b | ||||||||
| Yes vs. No | 0.523 (0.311-0.881) | 0.015 | 0.558 (0.323-0.965) | 0.037 | 0.412 (0.267-0.635) | <0.001 | 0.430 (0.273-0.680) | <0.001 |
| CEA level (ng/ml) c | ||||||||
| ≤5 vs. >5 | 1.249(0.840-1.856) | 0.272 | 1.453(1.046-2.019) | 0.026 | 1.460(1.046-2.037) | 0.026 | ||
| CA19-9 level (U/ml) d | ||||||||
| ≤37 vs. >37 | 1.446(0.965-2.166) | 0.074 | 1.191(0.847-1.675) | 0.315 | ||||
HR hazard ratio, CI confidence interval
a Data of 193 patients were available
b Radiofrequency ablation therapy within 3 months before or after hepatic resection
c Carcinoembryonic antigen before hepatic resection
d Cancer antigen 19-9 before hepatic resection